%PDF-1.4
%
35 0 obj
<>
endobj
32 0 obj
<>
endobj
103 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T18:51Z
2024-03-28T08:34:09-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T08:34:09-07:00
application/pdf
Heather
2002Ð199.nov
uuid:4d3853a9-1dd2-11b2-0a00-320a275dc400
uuid:4d3853ac-1dd2-11b2-0a00-810000000000
endstream
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
36 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
118 0 obj
[122 0 R]
endobj
119 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.0022 Tw 10 0 0 10 54 713.1616 Tm
(1977\2261978 cohort, but were reported in 16 cases \(19.8%\) in)Tj
0.1555 Tw 0 -1.2 TD
(the more recent time period. Use of allopurinol for acute)Tj
0.22321 Tw T*
(attacks seems to have declined substantially with 15.8%)Tj
0.2784 Tw T*
(reported use in the 1977\2261978 cohort and 4.9% in the)Tj
-0.02341 Tw T*
(1995\2261996 cohort. No reports of oxypurinol were evident in)Tj
0.0238 Tw T*
(either cohort and only 1 case of use of probenecid for treat-)Tj
0.23241 Tw T*
(ment of an acute attack was reported in the 1995\2261996)Tj
0 Tw T*
(cohort.)Tj
/TT1 1 Tf
-0.0002 Tc 0 -2.4 TD
(DISCUSSION)Tj
/TT0 1 Tf
0 Tc 0.2263 Tw 0 -1.2 TD
(Our study of 2 incidence cohorts separated by 20 years)Tj
0.0927 Tw T*
(demonstrates a statistically significant increase in the inci-)Tj
0.28709 Tw T*
[(dence of primary gout in the community of Rochester)39.8 (,)]TJ
0.3213 Tw T*
[(Minnesota. )17.8 (The incidence of secondary gout related to)]TJ
0.25681 Tw T*
[(thiazide diuretic therapy did not change over time. )17.8 (The)]TJ
0.09689 Tw T*
(evolving characteristics of the acute gout over the 20 year)Tj
0.00841 Tw T*
(interval of the study suggests that there is either a change in)Tj
-0.00011 Tc 0.1263 Tw T*
(presentation of gout or a more sophisticated awareness of)Tj
0 Tc 0.2858 Tw T*
(atypical gout by practitioners in the recent time period)Tj
0.0611 Tw T*
[(compared to the earlier time period or both. )17.8 (The decline in)]TJ
0.1263 Tw T*
(typical podagra and the increase in acute monoarthritis of)Tj
0.09801 Tw T*
(other joints including the upper extremity observed in this)Tj
0.1593 Tw T*
[(study support this conclusion. )17.7 (The increased use of diag-)]TJ
-0.0264 Tw T*
(nostic arthrocentesis in the evaluation of acute monoarthritis)Tj
0.2197 Tw T*
(in this community has likely led to the identification of)Tj
0.33791 Tw T*
(some of the atypical new cases. Despite this apparent)Tj
0.0681 Tw T*
(improvement in identifying gout, unrecognized tophaceous)Tj
0.1142 Tw T*
(gout is still encountered and was found in 5% of the new)Tj
0.02499 Tw T*
(cases identified in the latter cohort from the mid-1990s.)Tj
-0.00011 Tc 0.09331 Tw 1.2 -1.2 Td
(Although there is an increased awareness of the role of)Tj
0 Tc 0.1091 Tw -1.2 -1.2 Td
(diuretic therapy in the etiology of gout, we found a lower)Tj
-0.0056 Tw T*
(rate of thiazide diuretics exposure among patients first diag-)Tj
0.09509 Tw T*
(nosed with gout in the 1990s compared to the earlier time)Tj
-0.0204 Tw T*
(period. Other risk factors, which have remained stable in the)Tj
0.13049 Tw T*
[(gouty population including obesity)65 (, hypertension, diabetes)]TJ
-0.0106 Tw T*
(mellitus, and hyperlipidemia, emphasize the role that under-)Tj
0.1468 Tw T*
(lying metabolic risk factors and insulin resistance play in)Tj
0.0219 Tw T*
[(this disorder)54.9 (. Overall, our results indicate that the incidence)]TJ
0.1991 Tw 26.4 44.4 Td
(of primary gout \(i.e., unrelated to diuretic exposure\) has)Tj
0.17349 Tw T*
[(increased significantly over the past 20 years. )17.8 (While this)]TJ
0.21651 Tw T*
(increase might be a result of improved ascertainment of)Tj
0.0322 Tw T*
[(atypical gout, it may also be related to other)39.8 (, as yet uniden-)]TJ
0.1725 Tw T*
[(tified, risk factors. Clearly)64.9 (, gout will remain a frequently)]TJ
0.0325 Tw T*
(encountered rheumatic disorder in the US, especially as the)Tj
-0.00591 Tw T*
(prevalence of obesity and type 2 diabetes mellitus continues)Tj
-0.00011 Tc 0.02499 Tw T*
(to rise)Tj
0 Tc 0 Tw 6.5 0 0 6.5 342.9619 632.4615 Tm
[(1)56.7 (1,12)]TJ
10 0 0 10 357.2181 629.1616 Tm
(.)Tj
/TT1 1 Tf
-0.00011 Tc -3.9218 -2.4 Td
(ACKNOWLEDGMENT)Tj
/TT0 1 Tf
-0.02409 Tw 8 0 0 8 318 595.1616 Tm
(The authors wish to thank Ms. Deborah Fogarty for secretarial assistance\
in)Tj
0 Tc 0.02499 Tw 0 -1.25 TD
(the preparation of this manuscript.)Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 318 563.1616 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.02499 Tw 8 0 0 8 324.8 553.1616 Tm
[(1.)-800 (Acheson RM. Epidemiology of serum uric acid and gout: an)]TJ
1.55 -1.25 Td
(example of the complexities of multifactorial causation. Proc R Soc)Tj
T*
(Med 1970;63:193-7.)Tj
-1.55 -1.25 Td
[(2.)-800 (Acheson RM. Heberden Oration 1981: epidemiology and the)]TJ
1.55 -1.25 Td
[(arthritides. )54.9 (Ann Rheum Dis 1982;41:325-34.)]TJ
-1.55 -1.25 Td
[(3.)-800 (Healy LA, Hall )54.8 (AP)110.8 (. )17.7 (The epidemiology of hyperuricemia. Bull)]TJ
1.55 -1.25 Td
(Rheum Dis 1970;20:600-3.)Tj
-1.55 -1.25 Td
[(4.)-800 (Harris CM, Lloyd DC, Lewis J. )17.7 (The prevalence and prophylaxis of)]TJ
1.55 -1.25 Td
[(gout in England. J Clin Epidemiol 1995;48:1)36.9 (153-8.)]TJ
-1.55 -1.25 Td
[(5.)-800 (Klemp P)110.8 (, Stansfield SA, Castle B, Robertson MC. Gout is on the)]TJ
1.55 -1.25 Td
[(increase in New Zealand. )54.9 (Ann Rheum Dis 1997;56:22-6.)]TJ
-1.55 -1.25 Td
[(6.)-800 (Kurland L)91.8 (T)74 (, Molgaard CA. )17.7 (The patient record in epidemiology)65 (. Sci)]TJ
1.55 -1.25 Td
(Am 1981;245:54-63.)Tj
-0.00011 Tc -1.55 -1.25 Td
[(7.)-800.1 (W)79.7 (allace SL, Robinson H, Masi )54.8 (A)111 (T)73.9 (, Decker JL, McCarty DJ, )36.7 (Y)111 (u)-0.1 ( )17.7 (TF)79.7 (.)]TJ
1.55 -1.25 Td
(Preliminary criteria for the classification of the acute arthritis of)Tj
0 Tc T*
[(primary gout. )54.9 (Arthritis Rheum 1977;20:895-900.)]TJ
-1.55 -1.25 Td
[(8.)-800 (McCullagh P)110.8 (,)0.1 ( Nelder JA. Generalized linear models. 1 vol.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
0.533 w
508.756 392.362 m
527.179 392.362 l
S
BT
/TT0 1 Tf
-0.0002 Tc 0 Tw 8 0 0 8 529.379 393.1615 Tm
(New)Tj
0 Tc 0.02499 Tw -24.0224 -1.25 Td
[(Y)100.1 (ork: Chapman and Hall; 1983.)]TJ
-1.55 -1.25 Td
[(9.)-800 (Fam )54.8 (AG, Stein J, Rubenstein J. Gouty arthritis in nodal)]TJ
1.55 -1.25 Td
(osteoarthritis. J Rheumatol 1996;23:684-9.)Tj
-2.05 -1.25 Td
[(10.)-800 (Fam )54.9 (AG. Gout in the elderly)64.9 (. Clinical presentation and treatment.)]TJ
-0.02991 Tw 2.05 -1.25 Td
[(Drugs Aging )-54.9 (1998;13:229-43.)]TJ
-0.00011 Tc 0.02499 Tw -2.0131 -1.25 Td
[(1)36.8 (1)-0.1 (.)-800.1 (Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight)]TJ
0 Tc 2.0131 -1.25 Td
(and obesity in the United States: prevalence and trends, 1960-1994.)Tj
T*
(Int J Obes Relat Metab Disord 1998;22:39-47.)Tj
-0.00011 Tc -2.05 -1.25 Td
[(12.)-800.1 (Mokdad )54.8 (AH, Ford ES, Bowman BA, et al. Diabetes trends in the)]TJ
0 Tc 2.05 -1.25 Td
(U.S.: 1990-1998. [see comments]. Diabetes Care 2000;23:1278-83.)Tj
ET
1 w
54 54 m
558 54 l
S
BT
/TT2 1 Tf
8 0 0 8 420.9531 35.9844 Tm
[(The Journal of Rheumatology 2002; 29:1)74 (1)]TJ
0 Tw -45.8691 -0.0313 Td
(2406)Tj
ET
0 0 0 0 scn
/GS0 gs
104.45 59.08 407.5 -10.83 re
f*
0.5 w
104.45 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
77 0 obj
<>
endobj
109 0 obj
<>
endobj
41 0 obj
<>
endobj
46 0 obj
<>
endobj
39 0 obj
<>
endobj
38 0 obj
<>
endobj
67 0 obj
<>stream
HV lޛ]Y>06vClo͕̍{9e59@ȂPrP)$@ib+BJB8RpTJ'!"
>~?.Q/t
Pڑ%P`b JgvOk@]^9bHsk˧{ $C`鎫2QwDS;}[7ojk3KLN9"82@%诿(7P"^3̵nӂ!rvY?dB:'hs2)ZZ+Hs5VdѺrMhQu8yXbԡ21Uڎ(EgHl2A2c3v KH})?+`>v2v6Ơdu].NOTZH/'*V[;A?Fo!X
QA^o:ͼhؗyn+X
"(Ic `%6A\*Y_ؽï1
1'lǨ=1N[-VuaU40ƝiXu+㸂"NDX*S<2e:Xw$lGnKd..#poT^|Im҈dekX {둁|gU3tV?'8b$Sk9/z2_|FzGWnCv)mڴ~e|bcMU@͌fCxlR|J0u=cꁨ?6zz{
}=ٺ^'&s(͆zDtfDn}ɡg
}ƫWflԷJWl"?0)FlkDmJ/Xj
ڹŞlSSM͖YMۣMgghU;wgsaj +(
NJ>UdIo^I~">ZV6є郂eA,͊!b+)
{YgLotmI>[@#`S&wII[R~m(nn>kd'/f=<칏;yQ%G]GlN8VUÍU-Uqؾ?hjl]fr}3MއcJuWf]p{X6}QNQ~i4b=?ǔn"&
Q!c*o㿬WlS;%vNnL'&
6l*Af -I!iE[:`aaee@dRӂ4!-&mTss&3l#'+Vuiɕ
1g<,X83<@vxm%N*ۃ ̷4+f;Y>u}#S<|{=alC/=گG 7:$:>Qb?yy[; gv6]3I6%
#@4,vf#,X(y7YDuc^>DGptx?~2DȰ:!:WśM'@V N 2d (K'@:uWtdɏdtȨ^ Q'{2dud1F&.`#KhR&nJnmܚnSnS[HW֪ev+_u+Snn"A5[2Ѫ*J]U)ie
L
m+߄߇OHX
+Ua(3үW~ޯ+jOjBpk#7HYRa\=Oress><21:~!Yxd
Кxxd-.qu6XpRgRC!x)eqz7n@\V#oPpNʍ%a&+gxu?Eqz]pѣSZ:㙢7"o@vKrӟyxqw2SuHR|ǫÞ
r#{K6z7nNѵUUyv>rmrK!| 5ɧڤۚS%*xeYr&O}fE(u7nbERROmb?bj)L-bR@K69[6˙r&˲Qd¦'JZlF3#f,k2A'D29 vz ; /ΰd5'dwr7HHOCv3lLx!'G[pŇPnp-6b߹ni%,=ŗ;'IB⊖ qAbLb)5ze']X!h-ewq KBM㤞Q X=5\!?#ᓈ2s˺23YNrJvrE1K(%QqPJ2K<4zd1Oo=\l.͵ds342hGgeRƨc{Evdwlc IBH4J4ҌR\BaǛn3u(PgG0k~q?k.d'e7(D9Lm5uկN;OL$bg